Biblio
AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2023.
Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.
Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022.
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after failure of Chimeric antigen receptor T cell therapy (CAR-T) therapy. Transplant Cell Ther. 2022.
. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT). Transplant Cell Ther. 2021.
Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
Fecal microbiota transplantation: restoring the injured microbiome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018.
. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4(6):983-992.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Protocol for multi-site randomized trial of inpatient palliative care for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. Contemp Clin Trials. 2024:107460.
Quality of Life, Physical Functioning, and Psychological Distress of Older Adults Undergoing Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2023.
A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.